BridgeBio Pharma Net Income 2018-2024 | BBIO

BridgeBio Pharma net income from 2018 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
BridgeBio Pharma Annual Net Income
(Millions of US $)
2023 $-643
2022 $-481
2021 $-563
2020 $-449
2019 $-261
2018 $-131
2017 $-31
BridgeBio Pharma Quarterly Net Income
(Millions of US $)
2024-09-30 $-162
2024-06-30 $-73
2024-03-31 $-35
2023-12-31 $-168
2023-09-30 $-177
2023-06-30 $-158
2023-03-31 $-140
2022-12-31 $-138
2022-09-30 $-137
2022-06-30 $-10
2022-03-31 $-196
2021-12-31 $-147
2021-09-30 $-156
2021-06-30 $-96
2021-03-31 $-163
2020-12-31 $-120
2020-09-30 $-116
2020-06-30 $-121
2020-03-31 $-92
2019-12-31 $-73
2019-09-30 $-60
2019-06-30 $-66
2019-03-31 $-61
2018-12-31
2018-09-30 $-31
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00